2-(4-羟基-3-碘苯基)乙酸甲酯 | 352469-17-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 2-(4-羟基-3-碘苯基)乙酸甲酯
• 英文名称: methyl 2-(4-hydroxy-3-iodophenyl)acetate
• 英文别名: methyl 4-hydroxy-3-iodophenylacetate；(4-hydroxy-3-iodophenyl)acetic acid methyl ester
• CAS: 352469-17-1
• 化学式: C₉H₉IO₃
• 分子量: 292.073
• InChiKey: VYYIQILKQOKIKI-UHFFFAOYSA-N

物化性质

• 溶解度：
  溶于DCM、乙酸乙酯、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-羟基-3-碘苯基)乙酸甲酯 在 四丁基氯化铵 、 双(三甲基硅烷基)氨基钾 、 potassium carbonate 、 sodium iodide 、 sodium hydroxide 作用下， 以 甲醇 、 水 、 甲苯 、 乙腈 为溶剂， 反应 33.83h， 生成 盐酸奥洛他定
  参考文献：
  名称：

  抗组胺药奥洛他定及其E-异构体的立体选择性合成

  摘要：

  已经开发出抗组胺药物奥洛他定及其E-异构体的实用的立体选择性合成路线，关键步骤是使用不稳定的磷内酯和立体选择性Heck环化进行反式立体选择性Wittig烯化反应。Wittig反应的立体选择性取决于the盐阴离子和存在于用于产生叶立德的碱中的阳离子。

  DOI：

  10.1021/jo300925c
• 作为产物：
  描述：

  4-羟基苯乙酸甲酯 在 一氯化碘 、 正丁胺 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以29%的产率得到2-(4-羟基-3-碘苯基)乙酸甲酯
  参考文献：
  名称：

  Trace Amine-Associated Receptor Agonists:  Synthesis and Evaluation of Thyronamines and Related Analogues

  摘要：

  We have previously shown that several thyronamines, decarboxylated and deiodinated metabolites of the thyroid hormone, potently activate an orphan G protein-coupled receptor in vitro (TAAR1) and induced hypothermia in vivo on a rapid time scale [Scanlan, T. S.; Suchland, K. L.; Hart, M. E.; Chiellini, G.; Huang, Y.; Kruzich, P. J.; Frascarelli, S.; Crossley, D. A.; Bunzow, J. R.; Ronca-Testoni, S.; Lin, E. T.; Hatton, D.; Zucchi, R.; Grandy, D. K. 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat. Med. 2004, 10 (6), 638-642]. Herein, we report the synthesis of these thyronamines. Additionally, a large number of thyroamine derivatives were synthesized in an effort to understand the molecular basis of TAAR1 activation and hypothermia induction. Several derivatives were found to potently activate both rTAAR1 and mTAAR1 in vitro (compounds 77, 85, 91, and 92). When administered to mice at a 50 mg/kg dose, these derivatives all induced significant hypothermia within 60 min and exhibited a hypothermic induction profile analogous to 3-iodothyronamine (1, T(1)AM) except 91, which proved to be more efficacious. On the basis of this result, a dose-dependent profile for 91 was generated and an ED50 Of 30 mu mol/kg was calculated. Compound 91 proved to be more potent than T(1)AM for TAAR1 activation and exhibits increased potency and efficacy for hypothermia induction. These data further strengthen the pharmacological correlation linking TAAR1 activation by thyronamines and hypothermia induction in mice.

  DOI：

  10.1021/jm0505718

文献信息

• [EN] COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS ET MÉTHODES
  申请人：TEMPERO PHARMACEUTICALS INC

  公开号：WO2013019682A1

  公开（公告）日：2013-02-07

  The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORy.

  本发明涉及新型视黄醛酸相关孤儿受体γ（RORγ）调节剂及其在治疗由RORγ介导的疾病中的应用。
• [EN] PROCESS FOR THE PREPARATION OF 11-[(Z)-3-(DIMETHYLAMINO)PROPYLIDENE]-6,11-DIHYDRO-DIBENZ[B,E]OXEPIN-2-YL]-ACETIC ACID<br/>[FR] PROCESSUS DE PREPARATION D'ACIDE 11-[(Z)-3-(DIMETHYLAMINO)PROPYLIDENE]-6,11-DIHYDRO-DIBENZ[B,E]OXEPIN-2-YL]-ACETIQUE
  申请人：URQUIMA SA

  公开号：WO2006010459A1

  公开（公告）日：2006-02-02

  Process for the preparation of olopatadine (I), which comprises reacting a compound of formula (V) in the presence of a palladium catalyst to provide a compound of formula (VI), wherein the acid protecting group is removed to provide the compound of formula (I) and if desired, transformation into its salts.

  制备奥洛帕坦丁（I）的过程包括在钯催化剂存在下，使式（V）化合物发生反应，得到式（VI）化合物，其中酸保护基被去除以得到式（I）化合物，并且如有需要，转化为其盐。
• Compounds and methods
  申请人：Thompson K Scott

  公开号：US20050165045A1

  公开（公告）日：2005-07-28

  Disclosed is a compound of having the formula: pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.

  本发明揭示了一种化合物，其具有以下公式：其中结构变量如本文所定义，其药学上可接受的盐或溶剂化物以及含有其的制药组合物。本发明的化合物、盐和溶剂化物可用作LXR激动剂。
• 11 - [ (Z) -3- (Dimethylamino) Propylidene] - 6, 11-Dihydro-Dibenz [B,E] Oxepin-2-Yl] - Acetic Acid
  申请人：Bosch Cartes Joan

  公开号：US20090005579A1

  公开（公告）日：2009-01-01

  Process for the preparation of olopatadine (I), which comprises reacting a compound of formula (V) in the presence of a palladium catalyst to, provide a compound of formula (VI), wherein the acid protecting group is removed to provide the compound of formula (I) and if desired, transformation into its salts.

  制备奥洛帕替定（I）的过程，包括在钯催化剂的存在下，反应式（V）化合物以提供式（VI）化合物，其中酸保护基被去除以提供式（I）化合物，并且如果需要，转化为其盐。
• THYRONAMINE DERIVATIVES AND ANALOGS AND METHODS OF USE THEREOF
  申请人：Scanlan Thomas S.

  公开号：US20090105347A1

  公开（公告）日：2009-04-23

  Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed

  本发明涉及甲状腺胺衍生物和类似物，使用这些化合物的方法以及包含它们的药物组合物。本发明还揭示了制备这些化合物的方法。